COCP doses last subject in Phase 1b CDI-988 norovirus challenge
Cocrystal Pharma said it dosed the last subject in its Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.